Next-generation sequencing (NGS) and fluorescence-activated cell sorting (FACS) analysis confirmed that the mutational landscape and HLA-I haplotype of the PDX matched the patient’s primary tumor except for a subclonal ARID5B mutation (Extended Data Fig. 6b,c). This evidence concerns the gene ARID5B and neoplasm.